Holen Sie sich die Stockscreener-App
1.15
4.17%
-0.05
Handel nachbörslich:
1.10
-0.05
-4.35%
Schlusskurs vom Vortag:
$1.20
Offen:
$1.18
24-Stunden-Volumen:
742.80K
Relative Volume:
0.97
Marktkapitalisierung:
$52.59M
Einnahmen:
$19.94M
Nettoeinkommen (Verlust:
$-37.37M
KGV:
-1.1058
EPS:
-1.04
Netto-Cashflow:
$-33.38M
1W Leistung:
-12.21%
1M Leistung:
-40.41%
6M Leistung:
+24.86%
1J Leistung:
-48.66%
1-Tages-Spanne:
$1.07
$1.19
1-Wochen-Bereich:
$1.07
$1.33
52-Wochen-Spanne:
$0.595
$2.39
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Vergleichen Sie HOWL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.15 | 58.25M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
FY2025 Earnings Estimate for HOWL Issued By Leerink Partnrs - Defense World
Wedbush Expects Increased Earnings for Werewolf Therapeutics - Defense World
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for ... - Bluefield Daily Telegraph
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $295k By Investing.com - Investing.com South Africa
Werewolf Therapeutics: Multiple 10% owners sell $295k in shares By Investing.com - Investing.com Philippines
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $295k - Investing.com India
Werewolf Therapeutics: Multiple 10% owners sell $295k in shares - Investing.com India
Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $189,830 - Investing.com India
Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $189,830 By Investing.com - Investing.com Canada
[Form 4] Werewolf Therapeutics, Inc. Insider Trading Activity - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - MSN
How Werewolf Therapeutics Inc. stock performs after earningsJuly 2025 WrapUp & Verified Chart Pattern Signals - newser.com
Visual trend scoring systems applied to Werewolf Therapeutics Inc.July 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Werewolf Therapeutics Inc. stock trend forecastWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com
Is Werewolf Therapeutics Inc. stock bottoming out2025 Biggest Moves & Safe Swing Trade Setups - newser.com
Predicting Werewolf Therapeutics Inc. trend using moving averagesQuarterly Trade Report & Technical Entry and Exit Tips - newser.com
Will Werewolf Therapeutics Inc. price bounce be sustainableMarket Performance Recap & Community Consensus Stock Picks - newser.com
Will Werewolf Therapeutics Inc. stock outperform growth indexes2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
How to read the order book for Werewolf Therapeutics Inc.Analyst Upgrade & Technical Pattern Based Signals - newser.com
Analyzing recovery setups for Werewolf Therapeutics Inc. investors2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Advanced analytics toolkit walkthrough for Werewolf Therapeutics Inc.Weekly Investment Report & AI Based Buy and Sell Signals - newser.com
Will Werewolf Therapeutics Inc. stock recover faster than market2025 Market Outlook & Risk Managed Investment Signals - newser.com
Wedbush Halves Price Target on Werewolf Therapeutics to $3 From $6, Keeps Outperform Rating - MarketScreener
Werewolf Therapeutics Narrows Losses And Wins FDA Fast Track Nod - Finimize
Why Werewolf Therapeutics Inc. stock is rated strong buyTake Profit & Safe Capital Growth Stock Tips - fcp.pa.gov.br
Identifying reversal signals in Werewolf Therapeutics Inc.July 2025 Momentum & Consistent Profit Alerts - newser.com
What MACD signals say about Werewolf Therapeutics Inc.2025 Price Action Summary & Low Risk Entry Point Tips - newser.com
Werewolf Therapeutics Reports Q3 2025 Financial Results - TipRanks
Luke Evnin Sells 55,795 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 60,369 Shares - MarketBeat
Bioventures 2014 L.P. Mpm Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 114,044 Shares of Stock - MarketBeat
Ansbert Gadicke Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 114,044 Shares - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 94,063 Shares of Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $121,341.27 in Stock - MarketBeat
Werewolf Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
Werewolf Therapeutics Q3 net loss narrows on lower R&D expenses - MarketScreener
[8-K] Werewolf Therapeutics, Inc. Reports Material Event | HOWL SEC FilingForm 8-K - Stock Titan
Werewolf Therapeutics (NASDAQ: HOWL) says cash funds operations into Q4 2026 - Stock Titan
Is Werewolf Therapeutics Inc. reversing from oversold territory2025 Top Decliners & Proven Capital Preservation Methods - newser.com
Werewolf therapeutics director Evnin sells $251k in HOWL stock - Investing.com India
Werewolf therapeutics director Evnin sells $251k in HOWL stock By Investing.com - Investing.com Australia
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.44%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):